Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 66 out of 100. How common it is

Topic: Risk, prevention and care in population studies

Plain-language summary

Despite remarkable progress in the biomarker field in recent years, local validation of plasma biomarkers of Alzheimer’s disease (AD) and dementia is still lacking in Latin America. In this longitudinal cohort study of 145 elderly Brazilians, we assess the diagnostic performance of plasma biomarkers, based on clinical diagnosis and CSF biomarker positivity. Follow-up data of up to 4.7 years were used to determine performance in predicting diagnostic conversions. Participants were clinically categorized as cognitively unimpaired (n = 49), amnestic mild cognitive impairment (n = 29), AD (n = 38), Lewy body dementia (n = 22), or vascular dementia (n = 7). Plasma Tau, Aβ40, Aβ42, NfL, GFAP, pTau231, pTau181 and pTau217 were measured on the SIMOA HD-X platform. Plasma pTau217 showed excellent performance determining CSF biomarker status in the cohort, either alone (ROC AUC = 0.94, 95% CI: [0.88–1.00]) or as a ratio to Aβ42 (ROC AUC = 0.98, 95% CI: [0.94–1.00]). This study comprises an initial step towards local validation and adoption of dementia biomarkers in Brazil. Plasma biomarkers of Alzheimer’s disease and dementia are remarkable tools but still lack validation in Low and Middle-Income Countries. In this longitudinal study, authors report on the plasma biomarker profile of a Brazilian dementia cohort.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 49 participants. In this small Brazilian cohort of 145 elderly participants, plasma pTau217 showed excellent performance in determining CSF biomarker status, alone or as a ratio to Aβ42. Reported effect size: AUC = 0.94; AUC = 0.98.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Santos, L. E., Mattos, P., Pinheiro, T. C., Silva, A., Drummond, C., Sudo, F. K., et al. (2025). Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort. Nature Communications. https://doi.org/10.1038/s41467-025-56756-3

Vancouver

Santos LE, Mattos P, Pinheiro TC, Silva A, Drummond C, Sudo FK, et al. Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort. Nature Communications. 2025. doi:10.1038/s41467-025-56756-3. PMID: 40133253.

BibTeX

@article{santos2025-40133253,
  author  = {Santos, Luís E. and Mattos, Paulo and Pinheiro, TC and Silva, Ananssa and Drummond, Cláudia and Sudo, Felipe Kenji and Barros‐Aragão, Fernanda G. Q. and Vanderborght, Bart and others},
  title   = {{Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort}},
  journal = {Nature Communications},
  year    = {2025},
  doi     = {10.1038/s41467-025-56756-3},
  pmid    = {40133253},
  url     = {https://doi.org/10.1038/s41467-025-56756-3}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this small Brazilian cohort of 145 elderly participants, plasma pTau217 showed excellent performance in determining CSF biomarker status, alone or as a ratio to Aβ42. The authors describe this as an initial step toward local validation and adoption of dementia biomarkers in Brazil.

Study details

How this study scored 66/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 66 of 100.66 of 100 points earned34 not earned

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Nature Communications)
Journal's citation record 4 / 4 Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 49 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 23 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.7 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 14.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 2 / 4 Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Fernanda G. De Felice: h-index 66 (OpenAlex, whole career)
Institution's track record 1 / 3 Queen's University: institution h-index 794 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40133253)
Free to read 2 / 2 Free to read
Total 66 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in How common it is from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on How common it is

See all studies in How common it is →